BioNTech SE (BNTX) Current Deferred Revenue (2018 - 2024)

BioNTech SE (BNTX) has 7 years of Current Deferred Revenue data on file, last reported at $315.1 million in Q4 2024.

• For the quarter ending Q4 2024, Current Deferred Revenue fell 17.1% year-over-year to $315.1 million; the trailing twelve-month figure through Dec 2024 stood at $315.1 million (down 17.1% YoY), and the FY2024 full-year result was $315.1 million, down 17.1% from the prior year.
• Current Deferred Revenue slipped to $315.1 million in Q4 2024, from $380.1 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $442.9 million in Q4 2020 to a low of $78.7 million in Q4 2022.
• A 5-year average of $285.9 million and a median of $315.1 million in 2024 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue tumbled 63.05% in 2022 and jumped 383.25% in 2023, its largest moves.
• Tracing BNTX's Current Deferred Revenue over 5 years: stood at $442.9 million in 2020, then slumped by 51.94% to $212.9 million in 2021, then slumped by 63.05% to $78.7 million in 2022, then jumped by 383.25% to $380.1 million in 2023, then slipped by 17.1% to $315.1 million in 2024.
• Business Quant data shows BNTX's Current Deferred Revenue at $315.1 million in Q4 2024, $380.1 million in Q4 2023, and $78.7 million in Q4 2022.